Apogee Therapeutics, Inc.
APGE
Pozycja w akcjach
#2341
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Cena akcji
$135.07
Ostatnia synchronizacja: 2026-09-04
Kapitalizacja rynkowa
$8.36B
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
152.56%
Kraj
US
Handel Apogee Therapeutics, Inc. (APGE)
Kategoria
Healthcare
Historia ceny akcji dla Apogee Therapeutics, Inc. (APGE)
Najwyższa cena zamknięcia: $135.07 dnia 2026-09-01
Najniższa cena zamknięcia: $20.79 dnia 2023-07-01
Najniższa cena zamknięcia: $20.79 dnia 2023-07-01
Historia cen akcji firmy Apogee Therapeutics, Inc. od 2023 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 17.47% |
| 2025 | 60.85% |
| 2024 | 96.41% |
| 2023 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
